Bibiliografía
1. Colombo R, Gallipoli P, Castelli R. Thrombosis and hemostatic abnormalities in hematological malignancies. Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):441-50. [PubMed]
2. Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost JTH. 2010 Nov;8(11):2450-7. [PubMed]
3. Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Donati MB. Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta-analysis. J Thromb Haemost JTH. 2007 March;5(3):621-3. [PubMed]
4. Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Mariani G, de Gaetano G, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood. 2006 Oct;108(7):2216-22. [PubMed]
5. De Stefano V, Sorà F, Rossi E, Chiusolo P, Laurenti L, Fianchi L, et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost JTH. 2005 Sept;3(9):1985-92. [PubMed]
6. Hunault-Berger M, Chevallier P, Delain M, Bulabois C-E, Bologna S, Bernard M, et al. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica. 2008 Oct;93(10):1488-94. [PubMed]
7. Zwicker JI, Wang T-F, DeAngelo DJ, Lauw MN, Connors JM, Falanga A, et al. The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH. J Thromb Haemost JTH. 2020;18(2):278-84. [PubMed]
8. Sibai H, Chen R, Liu X, Falcone U, Schimmer A, Schuh A, et al. Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy. Br J Haematol. 2020 Dec;191(5):748-54. [PubMed]
9. Orvain C, Balsat M, Tavernier E, Marolleau J-P, Pabst T, Chevallier P, et al. Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study. Blood. 2020 Jul;136(3):328-38. [PubMed]
10. Wu Y-Y, Tang L, Wang M-H. Leukemia and Risk of Venous Thromboembolism: A Meta-analysis and Systematic Review of 144 Studies Comprising 162,126 Patients. Sci Rep. Apr 2017;7(1):1167. [PubMed]
11. Ku GH, White RH, Chew HK, Harvey DJ, Zhou H, Wun T. Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood. 2009 Apr;113(17):3911-7. [PubMed]
12. de la Serna J, Montesinos P, Vellenga E, Rayón C, Parody R, León A, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008 Apr;111(7):3395-402. [PubMed]
13. Kander EM, Zhao Q, Bhat SA, Hirsch J, Byrd JC, Ooka L, et al. Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib. Br J Haematol. 2019;187(3):399-402. [PubMed]
14. James DF, Werner L, Brown JR, Wierda WG, Barrientos JC, Castro JE, et al. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. J Clin Oncol Off J Am Soc Clin Oncol. 2014 Jul;32(19):2067-73. [PubMed]
15. Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogné J-M. Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis. JAMA Oncol. 2016 May;2(5):625-32. [PubMed]
16. Cortes JE, Kim D-W, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 26 de 2018;132(4):393-404. [PubMed]
17. Caruso V, Di Castelnuovo A, Meschengieser S, Lazzari MA, de Gaetano G, Storti S, et al. Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events. Blood. 2010 Jul;115(26):5322-8. [PubMed]
18. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008 May;111(10):4902-7. [PubMed]
19. Santi RM, Ceccarelli M, Bernocco E, Monagheddu C, Evangelista A, Valeri F, et al. Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL). Thromb Haemost. 2017 Apr; doi: 10.1160/TH16-11-0895. [PubMed]
20. Rupa-Matysek J, Gil L, Kaźmierczak M, Barańska M, Komarnicki M. Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: validation of the Khorana Risk Score. Med Oncol Northwood Lond Engl. 2017 Dec 4;35(1):5. [PubMed]
21. Lim SH, Woo S-Y, Kim S, Ko YH, Kim WS, Kim SJ. Cross-sectional Study of Patients with Diffuse Large B-Cell Lymphoma: Assessing the Effect of Host Status, Tumor Burden, and Inflammatory Activity on Venous Thromboembolism. Cancer Res Treat Off J Korean Cancer Assoc. 2016 Jan;48(1):312-21. [PubMed]
22. Antic D, Milic N, Nikolovski S, Todorovic M, Bila J, Djurdjevic P, et al. Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients. Am J Hematol. 2016 Oct;91(10):1014-9. [PubMed]
23. Bastos-Oreiro M, Ortiz J, Pradillo V, Salas E, Marínez-Laperche C, Muñoz A, et al. Incorporating genetic and clinical data into the prediction of thromboembolism risk in patients with lymphoma. Cancer Med. 2021 Nov;10(21):7585-92. [PubMed]
24. Borchmann S, Müller H, Hude I, Fuchs M, Borchmann P, Engert A. Thrombosis as a treatment complication in Hodgkin lymphoma patients: a comprehensive analysis of three prospective randomized German Hodgkin Study Group (GHSG) trials. Ann Oncol Off J Eur Soc Med Oncol. 2019 Aug;30(8):1329-34. [PubMed]
25. Cronin-Fenton DP, Søndergaard F, Pedersen LA, Fryzek JP, Cetin K, Acquavella J, et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer. 2010 Sept;103(7):947-53. [PubMed]
26. Auwerda JJA, Sonneveld P, de Maat MPM, Leebeek FWG. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica. 2007 Feb;92(2):279-80. [PubMed]
27. Sanfilippo KM, Luo S, Wang T-F, Fiala M, Schoen M, Wildes TM, et al. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol Nov. 2019;94(11):1176-84. [PubMed]
28. Li A, Wu Q, Luo S, Warnick GS, Zakai NA, Libby EN, et al. Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma. J Natl Compr Cancer Netw JNCCN. 2019 Jul;17(7):840-7. [PubMed]
29. Chakraborty R, Rybicki L, Wei W, Valent J, Faiman BM, Samaras CJ, et al. Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score. Blood. 2022 Dec 8;140(23):2443-50. [PubMed]
30. Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2012 Jan;119(4):933-9; quiz 1093. [PubMed]
31. Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol Off J Am Soc Clin Oncol. 2011 March;29(8):986-93. [PubMed]
32. Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka H-M, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 March;121(10):1720-8. [PubMed]
33. Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011 Jun;117(22):5857-9. [PubMed]
34. Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012 Dec;120(26):5128-33; quiz 5252. [PubMed]
35. Ruggeri M, Rodeghiero F, Tosetto A, Castaman G, Scognamiglio F, Finazzi G, et al. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood. 2008 Jan;111(2):666-71. [PubMed]
36. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol Off J Am Soc Clin Oncol. 2005 Apr;23(10):2224-32. [PubMed]
37. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004 Jan;350(2):114-24. [PubMed]
38. Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013 Jan;368(1):22-33. [PubMed]
39. McMahon B, Stein BL. Thrombotic and bleeding complications in classical myeloproliferative neoplasms. Semin Thromb Hemost. 2013 Feb;39(1):101-11. [PubMed]
40. Kaifie A, Kirschner M, Wolf D, Maintz C, Hänel M, Gattermann N, et al. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol OncolJ Hematol Oncol. 2016 March;9:18. [PubMed]
41. Zahid MF, Murad MH, Litzow MR, Hogan WJ, Patnaik MS, Khorana A, et al. Venous thromboembolism following hematopoietic stem cell transplantation-a systematic review and meta-analysis. Ann Hematol. 2016 Sep;95(9):1457-64. [PubMed]
42. Labrador J, Lopez-Anglada L, Perez-Lopez E, Lozano FS, Lopez-Corral L, Sanchez-Guijo FM, et al. Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients. Haematologica. 2013 Mar;98(3):437-43. [PubMed]
43. Johnsrud A, Craig J, Baird J, Spiegel J, Muffly L, Zehnder J, et al. Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. Blood Adv. 2021 Nov 9;5(21):4465-75. [PubMed]
44. A Decade of Experience in Peripherally Inserted Central Catheter (PICC) Related Thrombosis in Hematological Malignancies of a Single Spanish Center [Internet]. ISTH Congress Abstracts. [citado 29 de julio de 2020]. Disponible en: [Enlace]
45. Lv Y, Hou Y, Pan B, Ma Y, Li P, Yu L, et al. Risk associated with central catheters for malignant tumor patients: a systematic review and meta-analysis. Oncotarget. 2018 Feb;9(15):12376-88. [PubMed]
46. Mavrovounis G, Mermiri M, Chatzis DG, Pantazopoulos I. Peripherally Inserted Central Catheter lines for Intensive Care Unit and onco-hematologic patients: A systematic review and meta-analysis. Heart Lung J Crit Care. Nov-Dec 2020;49(6):922-933. [PubMed]
47. Chopra V, Kaatz S, Conlon A, Paje D, Grant PJ, Rogers M a. M, et al. The Michigan Risk Score to predict peripherally inserted central catheter-associated thrombosis. J Thromb Haemost JTH. 2017 Oct;15(10):1951-62. [PubMed]
48. Kahale LA, Tsolakian IG, Hakoum MB, Matar CF, Barba M, Yosuico VE, et al. Anticoagulation for people with cancer and central venous catheters. Cochrane Database Syst Rev. 2018 Jun;6:CD006468. [PubMed]
49. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol Off J Am Soc Clin Oncol. 2020 Feb;38(5):496-520. [PubMed]
50. Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021 Feb 23;5(4):927-74. [PubMed]
51. Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, et al.; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022 Jul;23(7):e334-e347. [PubMed]
52. Al-Ani F, Bermejo JMB, Mateos M-V, Louzada M. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review. Thromb Res. 2016 May;141:84-90. [PubMed]
53. Zoppellaro G, Veronese N, Granziera S, Gobbi L, Stubbs B, Cohen AT. Primary thromboembolic prevention in multiple myeloma patients: An exploratory meta-analysis on aspirin use. Semin Hematol. 2018 Oct;55(4):182-4. [PubMed]
54. Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, et al.; AVERT Investigators. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2019 Feb 21;380(8):711-9. [PubMed]
55. Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, et al.; CASSINI Investigators. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med. 2019 Feb 21;380(8):720-8. [PubMed]
56. Li A, Kuderer NM, García DA, Khorana AA, Wells PS, Carrier M, et al. Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: a systematic review and meta-analysis. J Thromb Haemost. 2019 Dec;17(12):2141-51. [PubMed]
57. Louzada ML, McCurdy A, Shivakumar SP, Quint A, Salib M, Lazo-Langner A, et al. Rivaroxaban for improvement in thromboembolism outcomes in patients with multiple myeloma on lenalidomide-based therapy: the rithmm feasibility pilot trial. Blood. 2021;138(Supplement 1):3232. Disponible en: [Enlace]
58. Sayar Z, Gates C, Bristogiannis S, Patel A, Ogunbiyi MO, Tailor A, et al. Safety and efficacy of apixaban as thromboprophylaxis in myeloma patients receiving chemotherapy: a prospective cohort study. Thromb Res. 2022 May;213:27-9. [PubMed]
59. Cornell RF, Goldhaber SZ, Engelhardt BG, Moslehi J, Jagasia M, Patton D, et al. Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy. Front Oncol. 2019 Feb 26;9:45. [PubMed]
60. Pegourie B, Karlin L, Benboubker L, Orsini-Piocelle F, Tiab M, Auger-Quittet S, et al. Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study. Am J Hematol. 2019 Jun;94(6):635-40. [PubMed]
61. Piedra K, Peterson T, Tan C, Orozco J, Hultcrantz M, Hassoun H, et al. Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis. Br J Haematol. 2022 Jan;196(1):105-9. [PubMed]
62. Storrar NPF, Mathur A, Johnson PRE, Roddie PH. Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens. Br J Haematol. 2019 Apr;185(1):142-4. [PubMed]
63. Pachón V, Trujillo-Santos J, Domènech P, Gallardo E, Font C, González-Porras JR, et al. Cancer-Associated Thrombosis: Beyond Clinical Practice Guidelines-A Multidisciplinary (SEMI-SEOM-SETH) Expert Consensus. TH Open Companion J Thromb Haemost. 2018 Nov;2(4):e373-86. [PubMed]
64. Lecumberri R, Ruiz-Artacho P, Trujillo-Santos J, Brenner B, Barillari G, Ruiz-Ruiz J, et al. Management and outcomes of cancer patients with venous thromboembolism presenting with thrombocytopenia. Thromb Res. 2020 Nov;195:139-45. [PubMed]
65. Kreher S, Ochsenreither S, Trappe RU, Pabinger I, Bergmann F, Petrides PE, et al. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.). Ann Hematol. 2014 Dec;93(12):1953-63. [PubMed]
66. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 Feb;378(7):615-24. [PubMed]
67. Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med. 2020 Apr;382(17):1599-607. [PubMed]
68. Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018 Jul 10;36(20):2017-23. [PubMed]
69. McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost. 2020 Feb;18(2):411-21. [PubMed]
70. Planquette B, Bertoletti L, Charles-Nelson A, Laporte S, Grange C, Mahé I, et al. CASTA DIVA Trial Investigators. Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial. Chest. 2022 Mar;161(3):781-90. [PubMed]
71. Giustozzi M, Agnelli G, Del Toro-Cervera J, Klok FA, Rosovsky RP, Martin A-C, et al. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis. Thromb Haemost. 2020 Jul;120(7):1128-36. [PubMed]
72. Al-Samkari H, Connors JM. Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy. Blood Adv. 019 Nov;3(22):3770-9. [PubMed]